v3.26.3
Condensed Statements of Operations and Comprehensive Income (Loss) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Operating expenses        
Research and development $ 31,575 $ 37,480 $ 121,774 $ 107,795
General and administrative 14,568 9,378 40,427 27,632
Total operating expenses 46,143 46,858 162,201 135,427
Loss from operations (46,143) (46,858) (162,201) (135,427)
Other income        
Interest income 16,496 6,192 26,214 17,848
Other income 3,065   3,065  
Gain on the Sevasemten Sale 1,348,066   1,348,066  
Total other income 1,367,627 6,192 1,377,345 17,848
Income (loss) before income tax expense 1,321,484 (40,666) 1,215,144 (117,579)
Income tax expense 155,333   155,333  
Net income (loss) 1,166,151 (40,666) 1,059,811 (117,579)
Other comprehensive income (loss):        
Unrealized (loss) gain on available-for-sale securities, net (5,102) 497 (6,279) 281
Total comprehensive income (loss) $ 1,161,049 $ (40,169) $ 1,053,532 $ (117,298)
Basic earnings (loss) per share (in dollars per share) $ 10.71 $ (0.39) $ 9.82 $ (1.15)
Diluted earnings (loss) per share (in dollars per share) $ 9.65 $ (0.39) $ 8.86 $ (1.15)
Weighted-average shares outstanding used in basic earnings (loss) per share (in shares) 108,870,331 105,492,779 107,892,028 101,892,400
Weighted-average shares outstanding used in diluted earnings (loss) per share (in shares) 120,874,085 105,492,779 119,643,866 101,892,400